News

Featured News

  • 2021 |
  • 2020 |
  • 2019 |
  • 2018 |
  • 2017 |
  • View All
  • News | September 17, 2021

    Skyhawk Therapeutics Completes New Investment Round

    Read More

    News | September 17, 2021

    DICE Therapeutics Announces Pricing of Upsized Initial Public Offering

    Read More

    News | September 17, 2021

    ImCheck Presents Preliminary Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at ESMO Congress 2021

    Read More

    Press Release | August 18, 2021

    Immunitas Therapeutics Completes $58 Million Series B Financing to Advance Pipeline into the Clinic and Expand Single Cell Analysis Drug Development Platform for Immuno-Oncology and Other Diseases

    Read More

    News | July 13, 2021

    ImCheck Publishes Seminal Paper in Cell Reports Elucidating How Butyrophilins Activate Vγ9Vδ2 T cell Function Against Tumor Cells

    Read More

    News | June 1, 2021

    Alloy Therapeutics and Pyxis Oncology Form Kyma Therapeutics to Develop Novel Immune-Modulating Antibodies for Cancer and Autoimmune Diseases

    Read More

    News | May 18, 2021

    Interius BioTherapeutics Raises $76M Series A Financing to Advance Breakthrough Cell and Gene Therapy Platform

    Read More

    Press Release | March 31, 2021

    Entrada Therapeutics Announces Closing of $116 Million Series B Financing

    Read More

    Press Release | March 30, 2021

    Pyxis Oncology Closes $152 Million Series B Financing to Further Advance Portfolio of Biologics

    Read More

    Press Release | March 18, 2021

    Pyxis Oncology Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Multiple Antibody-Drug Conjugates

    Read More

    News | March 18, 2021

    CAR-M era begins as Carisma doses first patient

    Read More

    News | January 8, 2021

    DiCE gets its ‘library’ card ready as it speeds development of DNA database-derived molecules with more investor cash

    Read More

    News | January 7, 2021

    CARISMA Therapeutics Completes Series B Funding to Advance Development of Novel CAR-Macrophage Immunotherapies

    Read More